HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $30 to $32.
August 04, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics' price target has been raised from $30 to $32 by HC Wainwright & Co., with a maintained 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Corcept Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100